KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Operating Margin (2016 - 2025)

Historic Operating Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 14854.78%.

  • CRISPR Therapeutics AG's Operating Margin rose 34392400.0% to 14854.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 1498.28%, marking a year-over-year decrease of 13344000.0%. This contributed to the annual value of 1250.38% for FY2024, which is 11904300.0% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Operating Margin is 14854.78%, which was up 34392400.0% from 25708.97% recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Operating Margin high stood at 84.67% for Q2 2021, and its period low was 2192350.0% during Q4 2022.
  • Its 5-year average for Operating Margin is 149585.3%, with a median of 17726.43% in 2024.
  • Its Operating Margin has fluctuated over the past 5 years, first plummeted by 2000000000bps in 2022, then soared by 2000000000bps in 2023.
  • CRISPR Therapeutics AG's Operating Margin (Quarter) stood at 1129.53% in 2021, then crashed by -193994bps to 2192350.0% in 2022, then skyrocketed by 100bps to 34.58% in 2023, then tumbled by -623bps to 180.96% in 2024, then plummeted by -8109bps to 14854.78% in 2025.
  • Its last three reported values are 14854.78% in Q3 2025, 25708.97% for Q2 2025, and 17158.84% during Q1 2025.